FDA Lifts Partial Clinical Hold on Phase II Trial of Novel Tumor Infiltrating Lymphocyte Cell Therapy for NSCLC
The FDA previously halted the IOV-LUN-202 trial following reports of a grade 5 serious adverse event that may have been linked to treatment with Iovance Biotherapeutics’ novel tumor infiltrating lymphocyte cell therapy LN-145, which is being evaluated in patients with advanced non–small cell lung cancer.
Image credit: Crystal light | stock.adobe.com
The FDA has removed a partial clinical hold on a Phase II trial evaluating Iovance Biotherapeutics’ novel tumor infiltrating lymphocyte (TIL) cell therapy LN-145 in patients with advanced non–small cell lung cancer (NSCLC).1 The FDA halted the IOV-LUN-202 trial (NCT04614103) in December 2023 following reports of a grade 5 serious adverse event (AE) that may have been linked to treatment with the non-myeloablative lymphodepletion preconditioning regimen.2
“In collaboration with the FDA and an independent data monitoring committee, Iovance developed additional safety measures and monitoring,” Iovance Biotherapeutics stated in a press release. “Upon reviewing this proposal, the FDA has cleared Iovance to resume patient enrollment in IOV-LUN-202.”
TILs are naturally occurring white blood cells in the immune system that can recognize and destroy cancer cells. For treatment with TIL cell therapy, the TILs are removed from a patient’s tumor and enhanced in a laboratory before being infused back into the patient to help the immune system recognize and eliminate the cancer cells.3
The open-label, multi-cohort, multicenter, nonrandomized IOV-LUN-202 trial is evaluating LN-145 in patients with unresectable or metastatic NSCLC without EGFR, ROS or ALK genomic mutations who received prior treatment with chemotherapy and anti-programmed cell death protein (PD)-1 therapy, as well as a minimum of one line of an approved targeted therapy if indicated by other actionable tumor mutations. This patient population has a poor prognosis with few treatment options, translating to a real-world overall survival (OS) of fewer than six months.3
Exclusion criteria included presence of symptomatic, untreated brain metastases; prior administration of an allogeneic organ transplant or prior cell therapy within the past 20 years; having any form of primary immunodeficiency; or an additional primary malignancy over the past three years.3
Before administration of LN-145, patients enrolled in the trial receive lymphodepletion comprised of cyclophosphamide and fludarabine. After a single infusion of the TIL cell therapy, patients also are administered interleukin-2 (IL-2).
The primary endpoint of IOV-LUN-202 is objective response rate (ORR) per central review, with secondary endpoints that include complete response (CR) rate, duration of response (DOR), disease control rate (DCR), progression-free survival, OS, and safety.
Preliminary trial data released in July 2023 found that among evaluable patients (n = 23) administered LN-145, the ORR was 26.1%, with one patient achieving a CR and five achieving a partial response, and a DCR of 82.6%. At the data cutoff date, median DOR was not yet reached (1.4+ months–9.7+ months).4
In terms of safety, treatment-emergent AEs were consistent with the known safety profiles of lymphodepletion and IL-2.
“Preliminary data from the IOV-LUN-202 trial support the potential benefit of one-time TIL therapy, including the opportunity for more durable responses than available second line chemotherapies,” Iovance Biotherapeutics stated in a press release. “An updated analysis in November of 2023 showed additional ongoing responses and duration of response greater than six months for 71% of the confirmed responders in the trial.”1
Iovance stated that enrollment of approximately 120 patients in the IOV-LUN-202 registrational cohorts is expected to be completed in 2025.
References
1. Iovance Biotherapeutics announces FDA has lifted clinical hold on the IOV-LUN-202 registrational trial in non-small cell lung cancer. News release. Iovance Biotherapeutics. March 4, 2024. Accessed March 5, 2024. https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-announces-fda-has-lifted-clinical-hold
2. Iovance Biotherapeutics announces clinical program update for LN-145 in non-small cell lung cancer. News release. Iovance Biotherapeutics. December 27, 2023. Accessed March 5, 2024. https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-announces-clinical-program-update-ln-145
3. Iovance Biotherapeutics. A Phase 2 Clinical Study for Metastatic Non-Small Cell Lung Cancer (NSCLC). Webpage. Updated 2023. Accessed March 5, 2024. https://www.lungcelltherapy.com/
4. Iovance Biotherapeutics announces regulatory and clinical updates for TIL therapy in advanced non-small cell lung cancer. News release. Iovance Biotherapeutics. July 10, 2023. Accessed March 5, 2024. https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-announces-regulatory-and-clinical-0
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.
Citius Pharmaceuticals Resubmits BLA to FDA for Lymphir to Treat Cutaneous T-Cell Lymphoma
March 19th 2024Pivotal Phase III Study 302 trial data show an objective response rate of 36.2% based on an independent review committee assessment in the treatment of relapsed/refractory cutaneous T-cell lymphoma.
